Reiner Tretter
Overview
Explore the profile of Reiner Tretter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
87
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shestakova M, Wilding J, Wilpshaar W, Tretter R, Orlova V, Verbovoy A
Diabetes Res Clin Pract
. 2018 Nov;
146:240-250.
PMID: 30391333
Aim: To assess the efficacy and safety of ipragliflozin as add-on therapy to metformin in Russian patients with type 2 diabetes mellitus. Methods: In this double-blind study conducted in 14...
2.
Hogenauer C, Mahida Y, Stallmach A, Marteau P, Rydzewska G, Ivashkin V, et al.
J Antimicrob Chemother
. 2018 Sep;
73(12):3430-3441.
PMID: 30260412
Objectives: Inflammatory bowel disease (IBD) poses an increased risk for Clostridium difficile infection (CDI). Fidaxomicin has demonstrated non-inferiority to vancomycin for initial clinical cure of CDI in patients without IBD;...
3.
Groen-Wijnberg M, van Dijk J, Krauwinkel W, Kerbusch V, Meijer J, Tretter R, et al.
Eur J Drug Metab Pharmacokinet
. 2016 Jun;
42(3):417-429.
PMID: 27350625
Background And Objectives: Mirabeg ron is a selective β3-adrenoceptor agonist approved for the treatment of overactive bladder (OAB). Four phase 1 studies were conducted in healthy subjects to evaluate the...
4.
Krauwinkel W, Kerbusch V, Meijer J, Tretter R, Strabach G, Van Gelderen E
Clin Pharmacol Drug Dev
. 2016 Apr;
2(3):255-63.
PMID: 27121787
Mirabegron, a selective β3 -adrenoceptor agonist, is approved for the treatment of overactive bladder (OAB). Solifenacin is a muscarinic receptor antagonist widely used in the treatment of OAB. This open-label,...
5.
Robinson D, Oelke M, Khullar V, Wijkstra H, Tretter R, Stow B, et al.
Neurourol Urodyn
. 2015 Jul;
35(7):819-25.
PMID: 26199198
Aims: Measurement of bladder wall thickness (BWT) by transvaginal ultrasound (TVUS) may be a less invasive method to diagnose overactive bladder (OAB) or detrusor overactivity (DO) and monitor response to...
6.
van Gelderen M, Tretter R, Meijer J, Dorrepaal C, Gangaram-Panday S, Brooks A, et al.
Int J Clin Pharmacol Ther
. 2014 Apr;
52(8):693-701.
PMID: 24755125
Objective: Tamsulosin and mirabegron may be used concomitantly in patients with lower urinary tract symptoms. Since alpha1-adrenoceptor antagonists are associated with cardiovascular side effects, potential pharmacokinetic and cardiovascular interactions were...
7.
Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, et al.
Eur J Drug Metab Pharmacokinet
. 2013 Jun;
39(1):43-52.
PMID: 23728524
Mirabegron is a potent and selective β3-adrenoceptor agonist developed for the treatment of overactive bladder. In vitro studies demonstrated that mirabegron partly acts as a (quasi-) irreversible, metabolism-dependent inhibitor of...
8.
Wagg A, Dale M, Tretter R, Stow B, Compion G
Eur Urol
. 2013 Mar;
64(1):83-4.
PMID: 23465518
No abstract available.
9.
Wagg A, Dale M, Tretter R, Stow B, Compion G
Eur Urol
. 2013 Jan;
64(1):74-81.
PMID: 23332882
Background: Compared with younger people, the elderly are more likely to suffer from overactive bladder (OAB) and to have other chronic conditions that affect physical or cognitive function. Despite this,...